David Shook - 15 Jan 2025 Form 4 Insider Report for Nkarta, Inc. (NKTX)

Role
Chief Medical Officer, Head of Research & Development
Signature
/s/ Alicia Hager, as Attorney-in-Fact
Issuer symbol
NKTX
Transactions as of
15 Jan 2025
Net transactions value
-$19,004
Form type
4
Filing time
17 Jan 2025, 17:37:19 UTC
Previous filing
07 Jan 2025
Next filing
11 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTX Common Stock Sale $19,004 -8,638 -4.3% $2.20 190,955 15 Jan 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person.

Remarks:

Chief Medical Officer, Head of Research & Development